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Abstract
Background. It has not yet been determined if the commonly reported cannabis–
psychosis association is limited to individuals with pre-existing genetic risk for psychotic
disorders.
Methods.We examined whether the relationship between polygenic risk score for schizophre-
nia (PRS-Sz) and psychotic-like experiences (PLEs), as measured by the Community
Assessment of Psychic Experiences-42 (CAPE-42) questionnaire, is mediated or moderated
by lifetime cannabis use at 16 years of age in 1740 of the individuals of the European
IMAGEN cohort. Secondary analysis examined the relationships between lifetime cannabis
use, PRS-Sz and the various sub-scales of the CAPE-42. Sensitivity analyses including covari-
ates, including a PRS for cannabis use, were conducted and results were replicated using data
from 1223 individuals in the Dutch Utrecht cannabis cohort.
Results. PRS-Sz significantly predicted cannabis use ( p = 0.027) and PLE ( p = 0.004) in the
IMAGEN cohort. In the full model, considering PRS-Sz and covariates, cannabis use was
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also significantly associated with PLE in IMAGEN ( p = 0.007). Results remained consistent in
the Utrecht cohort and through sensitivity analyses. Nevertheless, there was no evidence of a
mediation or moderation effects.
Conclusions. These results suggest that cannabis use remains a risk factor for PLEs, over and
above genetic vulnerability for schizophrenia. This research does not support the notion that
the cannabis–psychosis link is limited to individuals who are genetically predisposed to psych-
osis and suggests a need for research focusing on cannabis-related processes in psychosis that
cannot be explained by genetic vulnerability.
Introduction
Cannabis use is a well-studied risk factor for psychosis, schizo-
phrenia spectrum disorders and psychopathology in general.
Meta-analysis and systematic reviews have consistently shown
that there is a higher incidence of psychotic outcomes among can-
nabis users (Moore et al., 2007; Semple, McIntosh, & Lawrie,
2005) and that this relationship is dose dependent (Marconi, Di
Forti, Lewis, Murray, & Vassos, 2016). Using cannabis during
adolescence further increases risk for psychosis (Kelley et al.,
2016; Mustonen et al., 2018), earlier onset of psychotic symptoms
(Galvez-Buccollini et al., 2012) and worsened prognosis
(Manrique-Garcia et al., 2014). Although the epidemiological evi-
dence, along with some experimental evidence (D’Souza et al.,
2004), suggests a causal link between cannabis use and psychosis,
the nature of this relationship remains the focus of fierce debate
(Forti, Morgan, Selten, Lynskey, & Murray, 2019; Sommer &
van den Brink, 2019). Generally, three different hypotheses are
used to explain the mechanisms of the cannabis–schizophrenia
association: (1) the relationship is fully causal, i.e. cannabis use
causes schizophrenia, (2) the relationship may be partially con-
founded by shared genetic and environmental confounders and/
or reverse causation and (3) this link is entirely non-causal
(Gillespie & Kendler, 2021; Hiemstra et al., 2018).
Considering that part of the aetiology of cannabis use and
psychosis can be explained through heritable processes (Cardno
et al., 1999; Verweij et al., 2010), recent large scale genome-wide
association studies (GWASs) have demonstrated that multiple
single-nucleotide polymorphisms (SNPs) are associated with
risk for schizophrenia (Pardiñas et al., 2018), and predict cannabis
use behaviours (Johnson et al., 2020; Pasman et al., 2018).
Researchers can summarise the genetic risk for a disease through
polygenic risk score (PRS) calculations, derived from the sum-
mary statistics generated in these large-scale GWASs. Although
most PRSs for psychiatric diseases can currently only account
for a small portion of the variance of disease [approximately
<10% (Murray et al., 2021)], PRS can inform about shared genetic
aetiology among complex traits, and can also be used to estimate
the genetic risk to a trait at the individual level (Choi, Mak, &
O’Reilly, 2020). In view of the purported cannabis–psychosis
link, researchers have examined the link between polygenic risk
score for schizophrenia (PRS-Sz) and cannabis use. PRS-Sz has
been consistently associated with varying levels of cannabis use
across numerous cohorts (Carey et al., 2016; Guloksuz et al.,
2019; Hartz et al., 2017; Hiemstra et al., 2018; Jones et al., 2020;
Verweij et al., 2017). Consequently, some have concluded that
the relationship between PRS-Sz and cannabis use represents a
pathway from genetic risk for schizophrenia to cannabis use
(Jones et al., 2020), or that sensitivity to exposure to cannabis
use is moderated by PRS-Sz (Guloksuz et al., 2019). In contrast,
one highly powered study reported that PRS-Sz was not associated
with cannabis use disorder in healthy controls, or patients with
psychiatric disorders other than schizophrenia (Hjorthøj et al.,
2021). Furthermore, they report that the association between
prior cannabis use disorder and later development for schizophre-
nia was not altered after adjustment for PRS-Sz and PRS of other
psychiatric disorders (Hjorthøj et al., 2021), suggesting that the
association between cannabis use and development of schizophre-
nia is not explained by common genetic vulnerability (Hjorthøj
et al., 2021). Nevertheless, the results of most studies utilising
PRS-Sz, along with experiments employing discordant relative
designs (Giordano, Ohlsson, Sundquist, Sundquist, & Kendler,
2015) and studies using Mendelian randomisation (MR) techni-
ques (Gage et al., 2017; Pasman et al., 2018) support the second
hypothesis – mainly that the relationship between schizophrenia
and cannabis use is confounded by shared genetic vulnerability
and reverse causation.
The relationship between cannabis use and psychosis develop-
ment is particularly interesting in the adolescent ‘clinical high-risk
for psychosis’ (Fusar-Poli, 2017) population. These individuals are
at a high risk for psychosis in the presence of sub-clinical psych-
otic symptoms, functional decline and/or genetic risk (Fusar-Poli,
2017). As such, research on the developmental origins of psych-
osis risk has focused on the emergence of psychotic-like experi-
ences (PLEs) during the adolescent period and how cannabis
might influence such trajectories.
PLEs are highly prevalent sub-clinical psychotic symptoms
(Ronald et al., 2014), reported in up to 7% of individuals
(Linscott and van Os, 2013). Similar to the current models of
symptomatology in patients along the psychotic spectrum, these
sub-clinical symptoms have been further subdivided into various
dimensions, such as positive, negative and affective symptoms
(van Os & Reininghaus, 2016). Although these sub-clinical
experiences are transitory in about 80% of individuals, PLEs are
persistent in 20% of individuals (van Os et al., 2017). Moreover,
the presence of PLEs in community samples is associated with
increased odds for any mental disorder [odds ratio (OR) 3.08,
95% confidence interval (95% CI) 2.26–4.21], and psychotic dis-
orders (OR 3.96, 95% CI 2.03–7.73) (Healy et al., 2019).
Considering the close relationship of PLEs to psychotic disor-
ders, many have tested the hypothesis that cannabis use also
increases one’s risk for PLEs (see Ragazzi, Shuhama, Menezes,
& Del-Ben, 2018 for a systematic review). One study found that
cannabis use is significantly associated with the positive PLEs
(β = 0.061, p < 1 × 10−4), even after controlling for numerous con-
founding factors (van Gastel et al., 2012). Another study found
that the relationship between PLEs and cannabis use is increased
in the heaviest of cannabis consumers (Schubart et al., 2011); in
those who spend >€25/week on cannabis (i.e. heaviest users),
there was an increased odds for various domains of PLE such
as negative symptoms (OR 3.4, 95% CI 2.9–4.1), positive
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symptoms (OR 3.0, 95% CI 2.4–3.6) and depressive symptoms
(OR 2.8, 95% CI 2.3–3.3) (Schubart et al., 2011). Furthermore,
cannabis use has also been shown to temporally precede PLE in
adolescent cohorts (Bourque, Afzali, & Conrod, 2018), but PLEs
in childhood do not predict cannabis use (Jones et al., 2018a).
Overall, the study of PLE in cohorts of cannabis users may be
an interesting avenue to understand the nature and potential dir-
ectionality of the cannabis–psychosis relationship.
PRS-Sz are also related to PLE. Although initial studies
reported no relationship between PRS-Sz and PLEs (Derks
et al., 2012; Zammit et al., 2014), more recent studies – with
greater power – have found that PRS-Sz is associated with PLEs
(Jones et al., 2016, 2018b; Pain et al., 2018; Taylor et al., 2019).
But, there remains contradictory evidence in this field. For
example, some have reported that PRS-Sz is related to the negative
and affective symptom domains (Jones et al., 2016; Jones et al.,
2018b), but not positive symptoms (hallucinations, paranoia
and thought disturbance), whereas others have reported an asso-
ciation between PRS-Sz and positive symptoms (Pain et al., 2018;
Taylor et al., 2019).
Thus, although the relationship between polygenic risk for
schizophrenia and cannabis use has been consistently described
in the literature, and the link between cannabis use and psychotic-
like symptoms is shown to be significant, the relationship between
all three factors (polygenic risk, cannabis use and PLE) is not yet
fully understood. Although other studies have attempted to find
environmental factors that mediate the relationship between
PRS-Sz and cannabis use (Jones et al., 2020), to our knowledge
no study has examined if cannabis use mediates the relationship
between PRS-Sz and PLEs. Thus, considering that PRS-Sz may
be directly or indirectly linked to cannabis use, the current
study aims to investigate whether or not the pathway from genetic
vulnerability to psychosis symptoms, is at least partially mediated
by an indirect pathway through cannabis use.
In addition to the mediation hypothesis, we also test a moder-
ation hypothesis, in which cannabis use might exacerbate genetic
vulnerability to schizophrenia, and in turn increase the frequency
of PLE. Clarifying the moderating role of genetic vulnerability on
the relationship between cannabis and psychosis would also help
to inform decision making with regards to guidelines for recre-
ational cannabis in which individuals with a certain risk profile
could be advised accordingly, in addition to the existing literature.
These two hypotheses will be contrasted against a null hypothesis,
which postulates that despite any potential common genetic vul-
nerability to cannabis use and psychosis risk, the relationship
between cannabis use and psychosis risk holds, and is independ-
ent of (or in addition to) a common genetic vulnerability (i.e. can-
not be explained by common genetic vulnerability). To test all
hypotheses, we use a developmentally informed approach that
focuses on temporal precedence to confirm mediation between
variables. The current study uses data from two independent
European cohorts: we use data from the IMAGEN (Schumann
et al., 2010) study, a longitudinal study of over 2000 European
adolescents, as a discovery sample, and aim to replicate those
results in an independent European sample, the Utrecht cannabis
cohort (Schubart et al., 2011). The use of the IMAGEN cohort is
ideal considering that it allows for a longitudinal view of cannabis
use and PLE development, during the critical years of adoles-
cence. Furthermore, this cohort is relatively well powered to detect
mediation effects, as similarly sized cohorts have attempted to dis-
cern such effects using similar phenotypes (Jones et al., 2020).
This is compared with the cross-sectional Utrecht cannabis
cohort, which is a cohort that has been enriched for PLE and
heavy cannabis use; heavy cannabis use being a particularly strong




The IMAGEN study is a longitudinal imaging genetics study of
over 2000 healthy adolescents, mostly of European descent.
Detailed descriptions of this study, genotyping procedures and
data collection have previously been published (Schumann
et al., 2010). The current study uses data for the 2087 who con-
tributed their genetic data. The multicentric IMAGEN project
had obtained ethical approval by the local ethics committees (at
their respective sites) and written informed consent from all par-
ticipants and their legal guardians. The parents and adolescents
provided written informed consent and assent, respectively at
14 and 16, and then participants gave full consent at 18 and 21
years of age.
Utrecht cannabis cohort
Data from the Utrecht cannabis cohort come from a subset (N =
1223) of a large (N = 17 698) cohort of young Dutch participants,
for which genetic, cannabis use and PLE data were available.
Detailed descriptions of recruitment methods, genotyping proce-
dures and data collection were previously published (Boks et al.,
2020; Schubart et al., 2011). Participants gave online informed
consent, and the study received approval by the University
Medical Centre Utrecht medical ethical commission. Of note is
the enrichment for the extremes in PLE and cannabis use data
in the Utrecht cannabis cohort. To increase power for gene ×
environment interactions in previous studies (Boks et al., 2007),
data from individuals from the general population were combined
with data of participants selected from the top or bottom quintile
of total PLE scores, who are either non-users (<2 lifetime expo-
sures to cannabis) or heavy users (i.e. current expenditure for per-
sonal cannabis use exceeded €10 weekly).
Phenotype measures
Cannabis use measures
IMAGEN participants were repeatedly assessed for cannabis use
at 14, 16, 18 and 21 years of age using questions taken from the
European School Survey of Alcohol and other Drugs (ESPAD)
questionnaire. The ESPAD is a self-report questionnaire that mea-
sures the use of various drugs of abuse, including cannabis (Hibell
et al., 1997, 2004). With very few participants reporting cannabis
use at 14 years of age, we focus our analyses on data that were col-
lected at the 16-year-old assessment, using responses to the question
‘On how many occasions in your whole lifetime have you used
marijuana (grass, pot) or hashish (hash, hash oil)?’. Answers are
scored on a scale ranging from 0 to 6: ‘0’ = 0, ‘1–2 times’ = 1, ‘3–5
times’ = 2, ‘6–9 times’ = 3, ‘10–19 times’ = 4, ‘20–39 times’ = 5, ‘40
or more times’ = 6. In the Utrecht cannabis cohort, lifetime canna-
bis use data were reported according to the following categories:
never = 0, ‘1 time’ = 1, ‘2 times’ = 2, ‘5–9 times’ = 3, ‘>10 times’ = 4.
PLE measures
PLE data for both cohorts were drawn from the Community
Assessment of Psychic Experiences-42 (CAPE-42) questionnaire
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(Stefanis et al., 2002). CAPE-42 is a widely used self-report ques-
tionnaire that reliably measures lifetime PLEs (Mark &
Toulopoulou, 2016). The CAPE-42 has three subscales that meas-
ure positive, negative and depressive symptom dimensions. The
CAPE-42 measures frequency of symptoms, along with distress
caused by symptoms. We only analyse frequency scores as distress
and frequency scores are highly correlated in these cohorts
(r > 0.80). In the primary analyses, we use the sum total of frequency
scores, whereas we look at the various sub-dimensions in the sec-
ondary analysis. Due to the skewed distribution of scores, the log-
transformed sum score of each individual dimension and total
score of the frequency of symptoms was used. We used CAPE-42
data from the 18-year-old follow-up for the IMAGEN cohort.
Genetic data
IMAGEN
The genotyping was conducted using the Illumina Quad 610 chip
and 660Wq at the ‘Centre National de Genotypage’ (Paris,
France). Non-imputed autosomal SNPs are used for this study
(498 892 SNPs). Following all quality control steps, genetic data
(468 170 SNPs) remained for 1740 individuals. Baseline quality
control steps and principal component analysis to control for
ancestry are described in online Supplementary materials.
Utrecht
The genotyping in this cohort was conducted using either the
Illumina® HumanOmniExpress (733 202 SNPs; 576 individuals) or
the Illumina®Human610-QuadBeadchip (620 901 SNPs; 768 indivi-
duals). The CannabisQuest cohort genetic dataset was also imputed,
as described in Boks et al. (2020), using theHapMap III release 24 via
Beagle 5.2 imputation server (Browning and Browning, 2009). As
with the IMAGEN sample, quality control steps and principal com-
ponent analysis for ancestry are described in online Supplementary
materials. After all quality control steps, a total of 5 173 601 SNPs
and 1126 individuals remained for analysis.
Analysis
Polygenic risk scores
PRS-Sz were constructed for each of the IMAGEN and Utrecht
cannabis individuals, who passed genetic quality control.
PRS-Sz were built using data from the most recent schizophrenia
GWASs based on 40 675 cases and 64 643 controls (Pardiñas
et al., 2018) as a training set (for description of base set, see online
Supplementary materials). PRSs were built using PRScs (Ge,
Chen, Ni, Feng, & Smoller, 2019) and PLINK1.9 (Purcell).
PRScs is used to infer posterior SNP effect sizes, by placing a con-
tinuous shrinkage prior on SNP effect sizes reported in the most
recent schizophrenia GWASs (Ge et al., 2019), as well as an exter-
nal LD reference panel. Here, we use the publically available 1000
Genomes Project phase 3 panel (https://github.com/getian107/
PRScs). To calculate posterior effect sizes, in both cohorts, we
use the default settings of PRScs, described in more detail in
online Supplementary materials. After calculation of posterior
effect sizes, PRSs were calculated using the ‘--score’ function
and SUM modifier in PLINK1.9. After quality control, 321 567
variants are used to calculate PRS in the IMAGEN cohort, and
763 754 SNPs in the Utrecht cannabis cohort.
We aligned our analyses closely to the replication study, using
the same protocol to create PRS, and, in both IMAGEN and
Utrecht cannabis cohorts. To ease interpretability of results, we
scale the PRS, using the scale function in R (R Core Team,
2020). Using the same methods, we created a PRS for cannabis
use (PRS-Can), using publicly available data from the GWAS
studying lifetime cannabis use (Pasman et al., 2018) (a detailed
description of the base set can be found in online
Supplementary materials), to be used as a potential confounder.
Statistical analysis
Multiple multinomial linear regressions were used to assess the
relationships between PRS-Sz, cannabis use and PLEs in both
cohorts. For our primary analyses, we examine four distinct
models:
Model 1: The relationship between PRS-Sz, independent variable (IV),
and total CAPE score (log-transformed), dependent variable (DV).
Model 2: The relationship between PRS-Sz (IV) and lifetime cannabis use
(DV).
Model 3: The relationship between cannabis use (IV) and CAPE scores
(DV), when accounting for PRS-SZ.
Model 4: The interaction between PRS-Sz and cannabis use as predictors
of CAPE scores (moderation analysis).
We performed mediation analysis using maximum likelihood
estimation (MLE) path analysis to assess the effect of PRS-Sz on
PLE scores through the possible mediation effect of cannabis
use. As alluded to above, our hypothesis is that cannabis use
(M) mediates the relationship between PRS-Sz (independent vari-
able; IV) and PLE (dependent variable; DV). We report the bias-
corrected bootstrap 95% CI for the indirect effect, using an
adjusted bootstrap percentile method (BCa), based on 5000 boot-
strap samples. We use the MLE to handle missing data. All stat-
istical analyses are performed in R (R Core Team, 2020).
Mediation analysis was performed via the ‘lavaan’ (Rosseel
et al., 2021) and ‘tidySEM’ packages (van Lissa, 2021). An α =
0.05 was set for significance. Mediation analysis is only executed
using the IMAGEN data as this dataset is the only sample that
assessed cannabis use some years before the PLE assessment
and therefore the only dataset that can provide a true estimate
of a longitudinal relationship.
The association between PRS-Sz, cannabis use and the various
sub-domains of the CAPE-42 questionnaire was analysed in second-
ary analyses, through linear regression, in both cohorts. For all statis-
tical analyses of the IMAGEN cohort, we consider the following
potential confounders: sex, the first-six genetic principal components
(PCs). In the Utrecht cannabis cohort, we add age as a potential con-
founder. Finally, as a sensitivity analysis we include PRS-Can as a
potential confounder in regression analyses for the IMAGEN cohort.
Results
Sample characteristics
Characteristics of participants who passed genetic QC and
responded to cannabis use and PLE questionnaire data are
detailed in online Supplementary Table S2. Data from a total of
1740 individuals were used to calculate PRS-Sz in IMAGEN, and
1223 individuals in Utrecht cannabis cohort. In both IMAGEN
and Utrecht cannabis cohort samples, males report higher cannabis
use compared to females ( p < 0.001). The total frequency
of CAPE-42 symptoms reported is significantly greater in males
( p < 0.001) in the IMAGEN cohort. There was no difference in the
reported total CAPE-42 symptoms between males and females in
the Utrecht cannabis cohort (online Supplementary Table S2).
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Female participants in both cohorts report significantly higher scores
in the depression symptom sub-scale of the CAPE-42 ( p < 0.001).
Finally, the mean age of the Utrecht cannabis cohort is 20.5 years.
Regression models
Model 1: association of PRS-Sz with PLE
PRS-Sz predicted PLE in both cohorts (Table 1), when accounting
for covariates. PRS-Sz was significantly associated with CAPE-42
scores in both cohorts (βIMAGEN = 0.015 p = 0.004, R
2 = 0.019;
βUtrecht cannabis = 0.021, p = 0.0003, R
2 = 0.016). The results for
the full regression model, including covariates, are shown in
online Supplementary Table S3.
Model 2: association of PRS-Sz with cannabis use
After accounting for covariates, the PRS-Sz predicted cannabis
use in both cohorts (βIMAGEN = 0.097, p = 0.027, R
2 = 0.041;
βUtrecht cannabis = 0.24, p < 0.00001, R
2 = 0.17, Table 1). The results
for the regression model, including covariates, are shown in
online Supplementary Table S4.
Model 3: association of cannabis use with PLE
Cannabis use significantly predicted PLE in both cohorts
(βIMAGEN = 0.0091, p = 0.007, R
2 = 0.028; βUtrecht cannabis = 0.017,
p < 0.00001, R2 = 0.037; Table 1), when considering PRS-Sz and
all confounders. Moreover, PRS-Sz remained as a significant pre-
dictor ( p < 0.05) within this model in both cohorts (online
Supplementary Table S5).
Model 4: moderation analysis
In our moderation model, the interaction between cannabis
use and PRS-Sz was also not significant ( p > 0.05; online
Supplementary Table S6), suggesting that both cannabis use and
PRS-Sz independently predict PLE.
Mediation analysis
Although PRS-Sz predicted PLE at 18 years of age (Fig. 1, path c),
and lifetime cannabis use at 16 years of age (Fig. 1, path a), and
that cannabis use (16 years) was significantly associated with
PLE (18 years) (Fig. 1, path b), there was no evidence that
PRS-Sz influences PLE through previous cannabis use (β =
8.79 × 10−4, 95% CI −1.23 × 10−4 to 1.88 × 10−3, p = 0.08;
Table 2). For full results of path analysis, including covariates,
Table 1. Linear regression models
Independent variable β Std. error p R2
IMAGEN
Model 1 0.019
PRS-Sz 0.015 0.005 4.43 × 10−3
Model 2 0.041
PRS-Sz 0.097 0.044 2.72 × 10−2
Model 3 0.028
PRS-Sz 0.014 0.005 1.03 × 10−2
Cannabis use 0.009 0.003 6.91 × 10−3
Model 4 0.028
PRS-Sz 0.016 0.006 1.09 × 10−2
Cannabis use 0.009 0.003 6.29 × 10−3
PRS:cannabis −0.002 0.004 5.78 × 10−1
Utrecht
Model 1 0.016
PRS-Sz 0.021 0.006 3.11 × 10−4
Model 2 0.17
PRS-Sz 0.235 0.049 2.21 × 10−6
Model 3 0.037
PRS-Sz 0.017 0.006 3.48 × 10−3
Cannabis use 0.017 0.003 3.61 × 10−7
Model 4 0.037
PRS-Sz 0.017 0.008 4.13 × 10−2
Cannabis use 0.017 0.003 3.66 × 10−7
PRS:cannabis −0.00004 0.003 9.88 × 10−1
β, main effect size; std. error, standard error. Bold values indicate p < 0.05.
This table shows results of the effects of the independent variables in linear regression models. Dependent variable is log-transformed CAPE-42 scores for models 1-3-4, whereas dependent
variable for model 2 is lifetime cannabis use. We considered the first six PC and sex as covariates for all analyses and age is included for all analyses of the Utrecht cannabis cohort.
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see online Supplementary Table S7. Taken together, these results
suggest that both cannabis use and PRS-Sz independently
predict PLE.
Secondary analysis
The relationship PRS-Sz, cannabis use and the different sub-
domains in the CAPE-42 questionnaire was studied. In the
IMAGEN cohort (Table 3; online Supplementary Table S8),
PRS-Sz was significantly associated with the depression subscale
(βIMAGEN = 0.018, p = 0.01) and positive subscale (βIMAGEN =
0.011, p = 0.02). Moreover, cannabis use was predictive of the
depressive subscale (βIMAGEN = 0.01, p = 0.02) and negative symp-
toms subscale (βIMAGEN = 0.013, p = 0.003). Path analysis was also
performed, for the IMAGEN cohort, to detect mediation effects of
cannabis onto the different subscales, but it was not significant
( p < 0.05; online Supplementary Table S10). On the contrary, in
the Utrecht cannabis cohort, cannabis use was significantly asso-
ciated with all three sub-domains ( p < 0.005, Table 3, online
Supplementary Table S9), whereas PRS-Sz was significantly asso-
ciated with the depressive and negative subscales ( p < 0.005;
online Supplementary Table S9)
Sensitivity analysis
In the IMAGEN cohort, the three significant linear models (mod-
els 1–3) were reassessed considering PRS-Can as a potential con-
founder. The lifetime cannabis use PRS (PRS-Can) did not
predict cannabis use measures at 16 years of age, or CAPE scores
at 18 years of age ( p > 0.5). After including PRS-Cannabis a
covariable in model 3, both PRS-Sz and cannabis use remained
significant (βPRS-Sz = 0.014, p = 0.01, βCannabis Use = 0.009, p = 0.008).
Moreover, PRS-Sz significantly predicted cannabis use (model 2),
after inclusion of PRS-Can into the regression (β = 0.095, p = 0.03,
online Supplementary Table S11).
Discussion
In this study, we examine whether polygenic risk for schizophre-
nia predicts cannabis use, and higher levels of PLEs, in two inde-
pendent European ancestry cohorts. Furthermore, we explore
potential hypotheses through mediation and moderation analyses.
Our results demonstrate that cannabis use can be reliably pre-
dicted by PRS-Sz, strengthening the existing literature (Carey
et al., 2016; Hartz et al., 2017; Hiemstra et al., 2018; Jones et al.,
2020). The evidence of association between PRS-Sz and cannabis
use in the IMAGEN cohort has previously demonstrated by
French et al., that cannabis use at 14 years of age interacted
with PRS-Sz in decreasing cortical thickness from 14.5 to 18.5
years old (French et al., 2015). Here, we extend these findings
by showing that the PRS-Sz predicts PLE. This too is in line
with other study, using a variety in PLE assessments in various sub-
domains (Jones et al., 2016; Jones et al., 2018b; Pain et al., 2018;
Taylor et al., 2019). The current study confirms that PRS-Sz and
cannabis use are linked to risk for PLEs overall and in the depres-
sive and domains in both samples.
Considering the abundance of observational evidence showing
temporal precedence of cannabis use in risk for psychosis, a rea-
sonable alternative to a causal hypothesis is the proposal that can-
nabis use and PLE are explained through common genetic risk.
However, our findings do not confirm this explanation, despite
showing that PRS-Sz is correlated with both PLE and cannabis
Fig. 1. Results of mediation analysis. Independent variable = polygenic risk score for schizophrenia (PRS-Sz), dependent variable = log Total of CAPE-42 (CAPE),
Mediator = cannabis use. Although the effects of each path (a, b and c) are significant, the indirect path of PRS-Sz on PLEs as measured by the CAPE-42 question-
naire through cannabis use was not significant ( p > 0.05). The total effect was significant. The estimate is shown between arrows, with * signifying statistical sig-
nificance. *p < 0.05, **p < 0.01.
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outcomes in both cohorts. This is in line with recent study that
reported that various classes of cannabis use were associated
with increased risk for psychotic experiences, even after adjusting
for family history of schizophrenia (Jones et al., 2018a) and other
study adjusting for PRS-Sz (Jones et al., 2020). To our knowledge,
this is the first study to examine if cannabis use mediates the rela-
tionship between PRS-Sz and PLE. Through our longitudinal
design, our analyses did not find any evidence to support
mediation nor moderation hypotheses that explain the relation-
ship between lifetime cannabis use and PLE. Consequently,
these null findings suggest that despite the common genetic vul-
nerability of psychotic experiences, cannabis use and schizophre-
nia (Barkhuizen, Pain, Dudbridge, & Ronald, 2020; Pasman et al.,
2018), both PRS-Sz and cannabis use independently increase
one’s risk for PLE, leaving room for alternative explanations of
the cannabis–psychosis relationship.
Table 2. Mediation path analysis
Dependent variable Independent variable Label β S.E. z p value CI, lower CI, upper
CAPE
PRS c 0.014 0.005 2.698 0.007 0.004 0.024
Cannabis b 0.009 0.003 2.721 0.007 0.003 0.016
Cannabis
PRS a 0.097 0.044 2.217 0.027 0.011 0.182
Pathway effects
Cannabis indirect effect a × b 0.001 0.001 1.719 0.086 0.000 0.002
Total effect c + (a × b) 0.015 0.005 2.865 0.004 0.005 0.025
β, main effect size; S.E., standard error. Bold values indicate p < 0.05.
We report the results of the path analysis examining the link between PRS-Sz and PLE, and whether there is a significant indirect effect (mediation) through cannabis use. Here, we report,
estimates (β), S.E., z statistics and p value. We considered the first six PC and sex as covariates for all analyses. CIs are calculated adjusted bootstrap percentile method (BCa) based on 5000
bootstrap samples.
Table 3. Predictive value of PRS-Sz and cannabis use on CAPE-42 subscales
Independent variable β Std. error p R2
IMAGEN
Depressive sub-scale 0.065
PRS-Sz 0.018 0.007 1.12 × 10−2
Cannabis use 0.010 0.004 2.47 × 10−2
Negative sub-scale 0.020
PRS-Sz 0.014 0.007 5.28 × 10−2
Cannabis use 0.013 0.005 3.84 × 10−3
Positive sub-scale 0.021
PRS-Sz 0.011 0.005 2.76 × 10−2
Cannabis use 0.004 0.003 1.68 × 10−1
Utrecht
Depressive sub-scale 0.065
PRS-Sz 0.022 0.007 1.10 × 10−3
Cannabis use 0.010 0.004 7.17 × 10−3
Negative sub-scale 0.033
PRS-Sz 0.023 0.007 1.85 × 10−3
Cannabis use 0.019 0.004 7.17 × 10−6
Positive sub-scale 0.039
PRS-Sz 0.011 0.006 5.88 × 10−2
Cannabis use 0.017 0.003 9.24 × 10−8
β, main effect size; std. error, standard error. Bold values indicate p < 0.05.
This table shows results of the effects of the independent variables in linear regression models on the various sub-scales of the CAPE-42. Dependent variable is log-transformed CAPE-42
scores for each subscale. We considered the first six PC and sex as covariates for all analyses and age is included for all analyses of the Utrecht cannabis cohort.
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Two recent studies employed MR technique to investigate cau-
sal links between cannabis use and schizophrenia (Gage et al.,
2017; Vaucher et al., 2018). In both of these studies, there was
weak evidence to support the causal hypothesis in the direction
schizophrenia to cannabis use, while the reverse relationship
was strong (Gage et al., 2017; Vaucher et al., 2018). Although
these studies are limited by the power of the respective GWASs
used, recent study has called into question causal inferences
made in MR studies of complex traits (O’Connor & Price,
2018), and suggest the use of a latent causal variable (LCV)
instead. In LCV models, genetic correlation between ‘two traits
is mediated by a latent variable which has a causal effect on
each trait’ (O’Connor & Price, 2018). Accordingly, a recent
study examined the causal link between schizophrenia and life-
time cannabis use employing LCV and found no evidence for a
causal genetic link between the two (Jang et al., 2020). Taken
together, these reports do not preclude the possibility of a causal
mechanism linking cannabis use to psychosis. Instead, they –
along with the results presented above – suggest that psychosis
or psychosis risk, and cannabis use may be linked through
another environmental mediator rather than being linked through
a common genetic predisposition.
The findings of the current study suggest that the variance in
cannabis use that is most linked to PLEs is that which is not
accounted for by PRS-Sz. This is interesting and suggests that
future studies could focus on environmental factors influencing
cannabis behaviours, such as the type of cannabis used, or avail-
able in a given population, the effects of advertisements endorsed
by the cannabis industry, differing legalisation frameworks, and
cannabis potency, when attempting to understand the link
between cannabis and psychosis.
In secondary analysis of the current study, PRS-Sz was asso-
ciated with depressive and positive sub-domains of the
CAPE-42 in the IMAGEN cohort, whereas in the older Utrecht
cannabis cohort, PRS-Sz was associated with depressive and nega-
tive sub-domains, with results trending towards significance for
the positive sub-domain ( p = 0.058). Some previous reports
found no association between PLE-Sz and positive symptoms in
adolescent populations (Jones et al., 2016, 2018b; Zammit et al.,
2014). Nevertheless, one study has reported an association
between PRS-Sz and positive PLE symptoms in their adolescent
cohort (Pain et al., 2018), however, only when considering non-
zero responders, i.e. those who have already manifested positive
symptoms. Some have argued that the previously reported asso-
ciations between PLE-Sz and the positive symptom domain in
young adult populations can be explained by the fact that the gen-
etic overlap between positive and negative psychotic experiences
and schizophrenia might be stronger in adulthood than in adoles-
cence (Barkhuizen et al., 2020). As previously suggested by Jones
et al. (2016), this would imply that genetic risk for schizophrenia
is in fact associated with positive PLE, but that this risk may be
expressed in young adulthood rather than adolescence. Our
results seem to be in line with this interpretation, considering
that PLE in the IMAGEN cohort are reported at 18, i.e. the begin-
ning of young adulthood. On the contrary, other environmental
risk factors – such as cannabis use – may be what cause these
same positive symptoms in adolescents.
Limitations
Although the findings of this study are consistent with previous
independent studies, this study is not without limitations and
results should be interpreted accordingly. First, PRSs can only
explain small portions of the variances of the phenotypes they
study (Murray et al., 2021). In this study, PRS-Sz explained up
to 17% of the variance of cannabis use and 1.9% of variance of
PLE, when accounting for confounders. PRS also only incorpo-
rates data from common genetic variants; as such a significant
portion of the genetic effects may not be captured through the
PRS, such as the effects of rare variants and copy number var-
iants, which also may play a role in the pathogenesis of schizo-
phrenia (Malhotra & Sebat, 2012). Although a thorough
imputation procedure was implemented to deal with missing data
(Karahalios, Baglietto, Carlin, English, & Simpson, 2012), the
IMAGEN dataset had several missing data points, which could
bias our results. Next, considering the self-report nature of our
phenotypic measures, our results may be at risk for measurement
error, due to underreporting of symptoms, leading to weakened
power. Moreover, we use the PRS-Sz – which was built to predict
outcomes of clinical schizophrenia in adults – to predict PLEs in
adolescent and young adult populations. Although the PRS-Sz
has been used to reliably predict PLEs (Jones et al., 2016, 2018b;
Pain et al., 2018; Taylor et al., 2019), the most discriminant SNPs
for PLE may have not been captured by our PRS. However, consid-
ering the genetic overlap between schizophrenia and PLE
(Barkhuizen et al., 2020), our significant result remains informative.
Although our results consistently show that PRS-Sz is associated
with lifetime cannabis use, we cannot make any conclusions
about the effects of recent or current cannabis use. This is an
important limitation considering the recent literature which
demonstrates that current cannabis use is significantly associated
with psychotic experiences in the general population, but that life-
time cannabis use is not (Quattrone et al., 2020). Moreover, our
lifetime cannabis measure cannot account for potency or dose
effects. This is an important consideration, as previous
meta-analysis has shown heavy cannabis use with
high tetrahydrocannabinol (THC) content poses a particular risk
for psychosis (Marconi et al., 2016). Thus, future studies could con-
sider current use, and dose–response, when examining mediating
and moderating effects of cannabis on the PRS-Sz–psychotic
experience association.
Conclusion
In conclusion, although the current study could not confirm a
mediated pathway between schizophrenia risk and PLE through
cannabis use, the results contribute to the literature by showing
the positive relationship between cannabis and future psychotic-
like symptoms, while controlling for genetic vulnerability.
Although we do not confirm any causal hypotheses, this result
is important because, while cannabis producers would like to
claim that cannabis use is only contra-indicated for individuals
with a personal or family history of psychosis, the current findings
suggest that cannabis use remains a risk factor for PLEs, over and
above known genetic vulnerability for schizophrenia. Moreover,
there was no evidence that genetically vulnerable individuals
were more susceptible to the psychosis-related outcomes of ado-
lescent onset cannabis use. As suggested by other authors
(Jones et al., 2016), identifying a causal mechanism in the path-
way from cannabis use to psychosis is extremely important for
the development of targeted preventative interventions aimed at
reducing cannabis use and/or schizophrenia risk.
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